Guoping Jiang1,2, Ke Yu3, Lifang Shao4, Xiaobo Yu5,6, Chen Hu7, Pei Qian8,9, Haiyang Xie10,11, Jinjun Li12, Jie Zheng13, Shusen Zheng14,15. 1. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. jiangguoping@zju.edu.cn. 2. Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Hangzhou, China. jiangguoping@zju.edu.cn. 3. Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou, Zhejiang, 310029, China. yuke2009@gmail.com. 4. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. lfshao@hotmail.com. 5. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. yuxb@zju.edu.cn. 6. Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Hangzhou, China. yuxb@zju.edu.cn. 7. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. huchen@outlook.com. 8. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. cxqp1212@126.cm. 9. Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Hangzhou, China. cxqp1212@126.cm. 10. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. xiehy@zju.edu.cn. 11. Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Hangzhou, China. xiehy@zju.edu.cn. 12. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China. lijj64@gmail.com. 13. Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou, Zhejiang, 310029, China. zhengjie20141@163.com. 14. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, China. shusenzheng@zju.edu.cn. 15. Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Hangzhou, China. shusenzheng@zju.edu.cn.
Abstract
BACKGROUND: The association between epidermal growth factor (EGF) gene +61A/G polymorphism (rs4444903) and hepatocellular carcinoma (HCC) susceptibility has been widely reported, but the results were inconsistent. To clarify the effect of this polymorphism on HCC risk, a meta-analysis was performed. METHODS: The PubMed, Embase, Cochrane Library, Web of Science, Chinese BioMedical Literature (CBM), Wanfang and Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant studies published up to December 2013. Data were extracted independently by two authors. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to assess the strength of association. RESULTS: A total of 16 studies including 2475 HCC cases and 5381 controls were included in this meta-analysis. Overall, a significantly increased HCC risk was observed under all genetic models (G vs. A: OR = 1.383, P < 0.001, 95% CI: 1.174-1.629; GG vs. GA + AA: OR = 1.484, P < 0.001, 95% CI: 1.198-1.838; GG + GA vs. AA: OR = 1.530, P < 0.001, 95% CI: 1.217-1.924; GG vs. AA: OR = 1.958, P < 0.001, 95% CI: 1.433-2.675; GA vs. AA: OR = 1.215, P = 0.013, 95% CI: 1.041-1.418). In the subgroup analyses by ethnicity, a significant association with HCC risk was found in Asian populations (G vs. A: OR = 1.151, P = 0.001, 95% CI: 1.056-1.255), European populations (G vs. A: OR = 1.594, P = 0.027, 95% CI: 1.053-2.413, and African populations (G vs. A: OR = 3.599, P < 0.001, 95% CI: 2.550-5.080), respectively. CONCLUSIONS: Our study shows that EGF +61A/G polymorphism is significantly associated with the increased HCC risk, especially in Asian populations. Further large-scale and well-designed studies are required to confirm this conclusion.
BACKGROUND: The association between epidermal growth factor (EGF) gene +61A/G polymorphism (rs4444903) and hepatocellular carcinoma (HCC) susceptibility has been widely reported, but the results were inconsistent. To clarify the effect of this polymorphism on HCC risk, a meta-analysis was performed. METHODS: The PubMed, Embase, Cochrane Library, Web of Science, Chinese BioMedical Literature (CBM), Wanfang and Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant studies published up to December 2013. Data were extracted independently by two authors. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to assess the strength of association. RESULTS: A total of 16 studies including 2475 HCC cases and 5381 controls were included in this meta-analysis. Overall, a significantly increased HCC risk was observed under all genetic models (G vs. A: OR = 1.383, P < 0.001, 95% CI: 1.174-1.629; GG vs. GA + AA: OR = 1.484, P < 0.001, 95% CI: 1.198-1.838; GG + GA vs. AA: OR = 1.530, P < 0.001, 95% CI: 1.217-1.924; GG vs. AA: OR = 1.958, P < 0.001, 95% CI: 1.433-2.675; GA vs. AA: OR = 1.215, P = 0.013, 95% CI: 1.041-1.418). In the subgroup analyses by ethnicity, a significant association with HCC risk was found in Asian populations (G vs. A: OR = 1.151, P = 0.001, 95% CI: 1.056-1.255), European populations (G vs. A: OR = 1.594, P = 0.027, 95% CI: 1.053-2.413, and African populations (G vs. A: OR = 3.599, P < 0.001, 95% CI: 2.550-5.080), respectively. CONCLUSIONS: Our study shows that EGF +61A/G polymorphism is significantly associated with the increased HCC risk, especially in Asian populations. Further large-scale and well-designed studies are required to confirm this conclusion.
Authors: Kenneth K Tanabe; Antoinette Lemoine; Dianne M Finkelstein; Hiroshi Kawasaki; Tsutomu Fujii; Raymond T Chung; Gregory Y Lauwers; Yakup Kulu; Alona Muzikansky; Darshini Kuruppu; Michael Lanuti; Jonathan M Goodwin; Daniel Azoulay; Bryan C Fuchs Journal: JAMA Date: 2008-01-02 Impact factor: 56.272
Authors: R R Tönjes; J Löhler; J F O'Sullivan; G F Kay; G H Schmidt; W Dalemans; A Pavirani; D Paul Journal: Oncogene Date: 1995-02-16 Impact factor: 9.867
Authors: Ibrahim Baghdadi; Khaled Abu Ella; Ahmed El Shaaraway; Elsayed Elshayeb; Hala S El-Rebey; Mohamed El Hoseeny; Mary Naguib; Ali Nada Journal: Asian Pac J Cancer Prev Date: 2020-07-01
Authors: Tadeusz Osadnik; Joanna Katarzyna Strzelczyk; Rafał Reguła; Kamil Bujak; Martyna Fronczek; Małgorzata Gonera; Marcin Gawlita; Jarosław Wasilewski; Andrzej Lekston; Anna Kurek; Marek Gierlotka; Przemysław Trzeciak; Michał Hawranek; Zofia Ostrowska; Andrzej Wiczkowski; Lech Poloński; Mariusz Gąsior Journal: PLoS One Date: 2016-03-01 Impact factor: 3.240